Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2021: Research, Patents, Funding Events, Industry Partnerships, Biomedical Applications, Technologies, and Clinical Trials - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2021" report has been added to ResearchAndMarkets.com's offering.

The main objectives of this report are to describe the current status of iPSC research, patents, funding events, industry partnerships, biomedical applications, technologies, and clinical trials for the development of iPSC-based therapeutics.

Since the discovery of induced pluripotent stem cells (iPSCs) a large and thriving research product market has grown into existence, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number.

Therapeutic applications of iPSCs have surged in recent years. 2013 was a landmark year in Japan because it saw the first cellular therapy involving the transplant of iPSCs into humans initiated at the RIKEN Center in Kobe, Japan. Led by Masayo Takahashi of the RIKEN Center for Developmental Biology (CDB), it investigated the safety of iPSC-derived cell sheets in patients with macular degeneration.

In another world-first, Cynata Therapeutics received approval in 2016 to launch the world's first formal clinical trial of an allogeneic iPSC-derived cell product (CYP-001) for the treatment of GvHD.

Riding the momentum within the CAR-T field, Fate Therapeutics is developing FT819, its "off-the-shelf" iPSC-derived CAR-T cell product candidate. Numerous physician-led studies using iPSCs are also underway in Japan, a leading country for basic and applied iPSC applications.

iPS Cell Market Competitors

Today, FUJIFILM CDI has emerged as one of the largest commercial players within the iPSC sector. FUJIFILM CDI was founded in 2004 by Dr. James Thomson at the University of Wisconsin-Madison, who in 2007 derived iPSC lines from human somatic cells for the first time ever. The feat was accomplished simultaneously by Dr. Shinya Yamanaka's lab in Japan.

In 2009, ReproCELL, a company established as a venture company originating from the University of Tokyo and Kyoto University, made iPSC products commercially available for the first time with the launch of its human iPSC-derived cardiomyocytes, which it called ReproCario.

A European leader within the iPSC market is Ncardia, formed through the merger of Axiogenesis and Pluriomics. Founded in 2001, Axiogenesis initially focused on generating mouse embryonic stem cell-derived cells and assays, but after Yamanaka's iPSC technology became available, it became the first European company to license it in 2010. Ncardia's focus is on preclinical drug discovery and drug safety through the development of functional assays using human neuronal and cardiac cells.

In total, at least 68 distinct market competitors now offer various types of iPSC products, services, technologies and therapies.

Key Topics Covered:

1. Report Overview

2. Introduction

3. History Of Induced Pluripotent Stem Cells (iPSCS)

4. Research Publications On iPSCS

5. iPSCS: Patent Landscape

6. Clinical Trials Involving iPSCS

7. Funding For iPSCS

8. Generation Of Induced Pluripotent Stem Cells: An Overview

9. Human Ipsc Banking

10. Biomedical Applications Of iPSCS

11. Other Novel Applications Of iPSCS

12. Deal-Making Within The Ipsc Sector

13. Market Overview

14. Company Profiles

• Addgene, Inc.
• Aleph Farms
• Allele Biotechnology and Pharmaceuticals, Inc.
• ALSTEM, INC.
• American Type Culture Collection (ATCC)
• AMS Biotechnology Europe, Ltd. (AMSBIO)
• Applied Biological Materials, Inc. (ABM)
• Applied StemCell (ASC), Inc.
• Aruna Bio, Inc.
• Aspen Neuroscience, Inc.
• Axol Bioscience, Ltd.
• BD Biosciences
• Beckman Coulter Life Sciences
• BioCat GmbH
• BlueRock Therapeutics
• BrainXell
• Cell Biolabs, Inc.
• Cell Signaling Technology
• Cellaria
• CellGenix GmbH
• Cellular Dynamics International, Inc.
• Cellular Engineering Technologies (CET)
• Censo Biotechnologies, Ltd.
• Century Therapeutics, LLC
• CiRA
• Corning, Inc.
• Creative Bioarray
• Cynata Therapeutics Ltd.
• Cytovia Therapeutics
• DefiniGEN
• Evotec SE
• Fate Therapeutics, Inc.
• FUJIFILM Cellular Dynamics, Inc.
• GeneCopoeia, Inc.
• GenTarget, Inc.
• Heartseed, Inc.
• InvivoGen
• iPS Portal, Inc.
• iXCells Biotechnologies
• Lonza Group, Ltd.
• Megakaryon Corporation
• Merck/Sigma Aldrich
• Metrion Biosciences, Ltd.
• Miltenyi Biotec B.V. & Co. KG
• Ncardia
• NeuCyte
• Newcells Biotech
• Pancreatic MODY3
• PeproTech
• Phenocell SAS
• Platelet BioGenesis
• Pluricell Biotech
• PromoCell GmbH
• Qiagen
• R&D Systems, Inc.
• ReproCELL
• RHEINCELL Therapeutics GmbH
• Stemina Biomarker Discovery
• Synthego Corp.
• System Biosciences (SBI)
• Takara Bio
• Takeda Pharmaceutical Co., Ltd.
• TEMCELL Technologies
• Tempo Bioscience
• Thermo Fisher Scientific, Inc.
• TreeFrog Therapeutics
• VistaGen Therapeutics, Inc.
• Waisman Biomanufacturing
• xCell Science, Inc.
• Yashraj Biotechnology, Ltd.

   

   

For more information about this report visit https://www.researchandmarkets.com/r/sfsrza

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900